Infinity Bio is a Baltimore-based biotech company specializing in comprehensive antibody “reactome” profiling through its proprietary MIPSA technology. This platform uses DNA-barcoded antigen libraries and self-assembly to map interactions between antibodies and thousands of antigens in a single high-throughput assay. Supported by advanced bioinformatics and lab automation, Infinity Bio serves the research and clinical sectors, enabling breakthroughs in biomarker discovery, vaccine development, therapeutic design, and the study of allergies and autoimmune diseases.